Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 2
2020 1
2021 3
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Lois N; of the EMERALD Study Group. Lois N, et al. Ophthalmology. 2021 Sep;128(9):e46-e47. doi: 10.1016/j.ophtha.2021.05.014. Epub 2021 Jun 25. Ophthalmology. 2021. PMID: 34183173 No abstract available.
Evaluation of a New Model of Care for People with Complications of Diabetic Retinopathy: The EMERALD Study.
Lois N, Cook JA, Wang A, Aldington S, Mistry H, Maredza M, McAuley D, Aslam T, Bailey C, Chong V, Ganchi F, Scanlon P, Sivaprasad S, Steel DH, Styles C, Azuara-Blanco A, Prior L, Waugh N; EMERALD Study Group. Lois N, et al. Ophthalmology. 2021 Apr;128(4):561-573. doi: 10.1016/j.ophtha.2020.10.030. Epub 2020 Oct 31. Ophthalmology. 2021. PMID: 33130144 Free PMC article.
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial.
Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M; EMERALD study group. Orkin C, et al. Lancet HIV. 2018 Jan;5(1):e23-e34. doi: 10.1016/S2352-3018(17)30179-0. Epub 2017 Oct 6. Lancet HIV. 2018. PMID: 28993180 Clinical Trial.
Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And new vesseLs in Diabetic retinopathy (EMERALD).
Lois N, Cook J, Aldington S, Waugh N, Mistry H, Sones W, McAuley D, Aslam T, Bailey C, Chong V, Ghanchi F, Scanlon P, Sivaprasad S, Steel D, Styles C, McNally C, Rice R, Prior L, Azuara-Blanco A; EMERALD Study Group. Lois N, et al. BMJ Open. 2019 Jun 28;9(6):e027795. doi: 10.1136/bmjopen-2018-027795. BMJ Open. 2019. PMID: 31256030 Free PMC article.
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, Lathouwers E, Hufkens V, Jezorwski J, Petrovic R, Brown K, Van Landuyt E, Opsomer M; EMERALD study group. Eron JJ, et al. Antiviral Res. 2019 Oct;170:104543. doi: 10.1016/j.antiviral.2019.104543. Epub 2019 Jul 4. Antiviral Res. 2019. PMID: 31279073 Free article. Clinical Trial.